How long do you treat with immunotherapy patients with MSI-high T4B initially unresectable colon adenocarcinoma?
And is it different when using pembrolizumab or a combination of ipilimumab/nivolumab?
Answer from: Medical Oncologist at Community Practice
Immunotherapy is an established treatment option for dMMR/MSI-H metastatic colorectal cancer (mCRC) but its optimal duration remains to be determined. A fixed duration of 2 years or until progression or toxicity has been adopted based on the KEYNOTE-177 study. More recently, the GERCOR NIPICOL phase...
Answer from: Medical Oncologist at Community Practice
There is limited prospective evidence that I am aware of to guide management in this situation. If the patient is responding to and tolerating immunotherapy for unresectable dMMR colon cancer, then I would likely continue therapy until either 1) completion of two years of therapy (as per KN-177), 2)...
Comments
Medical Oncologist at The Center for Hematology and Oncology at Holy Cross Hospital Agree
Medical Oncologist at City of Hope Orange County To add to Dr. @Copur and Dr. @Brooks' discuss...